<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 3; Issue 4</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(Jul-Aug, 2022)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Clinical Case Reports</ArticleType>
      <ArticleTitle>A Case Report of Plasmablastic Lymphoma with Unusual Presentation: How Do Socioeconomic Factors Contribute to Cancer Survival?</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>10</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Precious</FirstName>
          <LastName>Idogun</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Janevi</FirstName>
          <LastName>Rebernigg</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Yeshanew</FirstName>
          <LastName>Teklie</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Alan</FirstName>
          <LastName>King</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Ning</FirstName>
          <LastName>Ke</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Plasmablastic lymphoma (PBL) is an uncommon but aggressive subtype of diffuse large B-cell lymphoma (DLBCL) that is mostly seen in HIV positive patients. This case report details an HIV-positive patient with two unusual sites of PBL manifestation, the pleural space and the rectum. The patient was initiated on treatment but subsequently developed complications leading to the inability to temporarily continue therapy. In addition to illustrating less common site manifestations of PBL as well as its therapeutic challenges, this case also exhibits how a patient’s socioeconomic and health insurance status can contribute to treatment delays, and hence their overall prognosis and survival.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Plasmablastic Lymphoma,HIV,AIDS,Health Insurance,Cancer Survival</Keywords>
      <URLs>
        <Abstract>https://www.jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=13914&amp;title=A Case Report of Plasmablastic Lymphoma with Unusual Presentation: How Do Socioeconomic Factors Contribute to Cancer Survival?</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Al Sbihi AF, Singh P, Manasrah N, Kandah E, Appel J. An HIV associated plasmablastic lymphoma with spontaneous tumor lysis syndrome. Cureus 2020; 12(8).&#13;
&#13;
Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood 2015; 125: 2323-2330.&#13;
&#13;
Castillo JJ and Reagan JL. Plasmablastic Lymphoma: A systematic review. The Scientific World Journal 2011; 11: 687-696.&#13;
&#13;
Goldstein JS, Nastoupil LJ, Han X, Jemal A, Ward E, Flowers CR. Disparities in survival by insurance status in Follicular lymphoma. Blood 2018; 132: 1159-1166.&#13;
&#13;
Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, O’Sullivan DE, Booth CM, Sullivan R, Aggarwal A. Mortality due to cancer treatment delay: Systematic review and meta-analysis. BMJ 2020; 371: m4087.&#13;
&#13;
Martin S, Ulrich C, Munsell M, Taylor S, Lange G, Bleyer A. Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist 2007; 12: 816-824.&#13;
&#13;
Morscio J, Dierickx D, Nijs J, Verhoef G, Bittoun E, Vanoeteren X, Wlodarska I, Sagaert X, Tousseyn T. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and Posttransplant patients. Am J Surg Pathol 2014; 38: 875-886.&#13;
&#13;
Nwanwene K, Khan NA, Alsharedi M. Testicular plasmablastic lymphoma in an HIV-negative patient: A rare case presentation. J Investig Med High Impact Case Rep 2021; 9: 232470962110174.&#13;
&#13;
Pathak P, Madi DR, PV SR, Kassim S, Anusha S. Primary adrenal plasmablastic lymphoma presenting as lymphomatous meningitis – a diagnostic perplexity. Cytopathology 2021; 33: 123-126.&#13;
&#13;
Pokhrel A, Yuldasheva O, Mirashi E, Nair K, Salyana M, Jaswani V, Avezbakiyev B, Wang JC. Plasmablastic lymphoma presenting as extensive peritoneal and retroperitoneal nodules in an HIV-positive patient. J Investig Med High Impact Case Rep 2022; 10: 232470962110656.&#13;
&#13;
Tao L, Foran JM, Clarke CA, Gomez SL, Keegan TH. Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood 2014; 123: 3553-3562.&#13;
&#13;
Yabroff KR, Reeder-Hayes K, Zhao J, Halpern MT, Lopez AM, Bernal-Mizrachi L, Collier AB, Neuner J, Phillips J, Blackstock W, Patel M (2020). Health Insurance Coverage Disruptions and Cancer Care and Outcomes: Systematic Review of Published Research. J Natl Cancer Inst 2020; 112: 671–687.&#13;
&#13;
Web-Links:&#13;
&#13;
&#13;
	Cancer disparities. National Cancer Institute. https://www.cancer.gov/about-cancer/understanding/disparities. Accessed June 2, 2022.&#13;
	Justin R Hofmann MD. Prevention of opportunistic infections (OI) in patients with HIV infection: General guidelines for prophylaxis, exposure avoidance, initiation of prophylaxis and treatment. Prevention of Opportunistic Infections (OI) in Patients with HIV Infection: General Guidelines for Prophylaxis, Exposure Avoidance, Initiation of Prophylaxis and Treatment. https://emedicine.medscape.com/article/1529727-overview#a8. Published July 19, 2021. Accessed June 21, 2022.&#13;
	Zelentz A, Gordon L, Abramson J. B-Cell lymphomas. NCCN Guidelines Version 4.2022 B-Cell Lymphomas. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Published April 1, 2022. Accessed June 9, 2022.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>